AI in Drug Discovery
Jul 13, 2021
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Apr 23, 2021
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Wired Health w/ Joanna Shields
Mar 31, 2021
Join BenevolentAI’s CEO Joanna Shields at Wired Health where she will be speaking about forging new frontiers in drug discovery by uniting human and artificial intelligence
Cambridge Science Festival / Anne Phelan
Mar 31, 2021
Join BenevolentAI’s Chief Scientific Officer at Cambridge Science Festival where she will be speaking about Data science, AI and their potential to transform the discovery and development of medicines.
LSX World Congress w/ Jackie Hunter
Feb 2, 2021
Join Jackie Hunter at the LSX World Congress where she will discuss AI in drug discovery and development in a panel alongside leaders from Atomwise, Arctoris, Sensyne Health.
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Jan 15, 2021
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.